Nexus takes 79.6% of BioForce Nanosciences in $400K share buy
What's the deal? Nexus Capital InvestmentsDealroom has a profile for this one. Try Dealroom → has acquired 26,700,000 common shares of BioForce Nanosciences HoldingsDealroom has a profile for this one. Try Dealroom → for $400,000, giving it roughly 79.6% of the company. The purchase, disclosed in a Schedule 13D executed on September 4, 2026, was financed through Nexus's operational working capital.
The terms: The shares represent about 79.6% of BioForce's 33,549,005 outstanding common shares as of June 30, 2026. Each share carries a par value of $0.001. Gretchen Privett, president and secretary of Nexus, signed the filing.
The fine print: Nexus reported no other BioForce trades in the past 60 days beyond those in the filing, and no other parties hold rights to dividends or proceeds from the shares.
What's the endgame? The majority stake gives Nexus reserved rights to pursue mergers or acquisitions, sell or transfer significant assets, and change management, the board, or the capital structure. Both companies retain those rights, though the filing states no such actions are currently planned.
The signal: A private, low-cost purchase of a controlling stake gives Nexus broad optionality over BioForce's future direction without committing to any immediate change. For now, the deal is a placeholder for control rather than a plan of action.
Image credit: Generated with Gemini
